GSK signs $196 mln U.S. anthrax treatment deal
LONDON, Sept 19
LONDON, Sept 19 (Reuters) - Britain's GlaxoSmithkline said it had signed a new four-year deal worth $196 million to supply the U.S. government with its inhalation anthrax treatment, raxibacumab, in case of a potential bio-terrorist attack.
GSK said on Thursday that it would supply 60,000 doses of the treatment to the Biomedical Advanced Research and Development Authority, part of the U.S. Department of Health and Human Services.
- Washington, DC city council raises minimum wage to $11.50/hr in 2016
- China confirms near miss with U.S. ship in South China Sea
- UPDATE 5-Mega Millions lottery winning tickets sold in California, Georgia -Officials
- Winning ticket sold in California for Mega Millions lottery: official |
- India removes barriers to U.S. embassy as anger grows over diplomat's arrest